Detemir as a once-daily basal insulin in type 2 diabetes
Scott E NelsonCleveland Family Medicine, Cleveland, Mississippi, USABackground: Insulin detemir, a long-acting basal insulin analog, is labeled for once-daily or twice-daily dosing in patients with type 1 (T1DM) or type 2 (T2DM) diabetes mellitus. Protocols for some earlier clinical studies of detem...
Guardado en:
Autor principal: | Nelson SE |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ad47ba1e910c475d90a90f63ba67946a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes
por: Noo Ree Cho, et al.
Publicado: (2021) -
Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy
por: Sunkaraneni S, et al.
Publicado: (2017) -
Effect of statin therapy on vaspin levels in type 2 diabetic patients
por: Al-Azzam SI, et al.
Publicado: (2013) -
The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies
por: Davies M, et al.
Publicado: (2016) -
Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study
por: Rambiritch V, et al.
Publicado: (2014)